Obagi Medical announced new collaborations with Schweiger Dermatology and It’s a Secret Med Spa as part of its ALOHA (Aesthetics Leadership with Obagi’s Hyaluronic Acid) program, extending the reach of its first FDA‑approved injectable, saypha MagIQ.
The partnership with Schweiger Dermatology was announced on February 27, 2026. The agreement allows Schweiger’s clinicians to administer saypha MagIQ across its 160‑plus offices in eight states and to collect structured real‑world data that will feed into Obagi’s ALOHA program.
The It’s a Secret Med Spa partnership was announced on February 25, 2026. The luxury med‑spa chain will provide its providers hands‑on experience with saypha MagIQ and participate in the same data‑collection effort, giving Obagi a foothold in high‑volume, high‑quality practice settings in Texas, Arizona and Washington, D.C.
These collaborations are part of Obagi’s broader strategy to enter the U.S. dermal filler market after the September 2025 FDA approval of saypha MagIQ. The ALOHA program is designed to generate real‑world evidence that complements clinical trial data and supports future regulatory and commercial initiatives.
By partnering with a large dermatology group and a premium med‑spa chain, Obagi gains access to diverse patient populations and practice environments, positioning it to accelerate market share gains against established competitors such as Allergan, Galderma, Revance and Evolus.
Waldencast plc’s goal of doubling Obagi’s total addressable market by 2029 is reinforced by these partnerships, which also provide data that could inform pricing, reimbursement and product development strategies.
The new agreements represent a significant operational milestone for Obagi, strengthening its market entry strategy and laying the groundwork for future growth in the U.S. aesthetic market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.